PI3K/AKT/mTOR通路抑制剂在膀胱癌中的研究进展

Research progress of PI3K/AKT/mTOR pathway inhibitors in bladder cancer

磷脂酰肌醇3-激酶(PI3K)/AKT/哺乳动物雷帕霉素靶标(mTOR)通路在人类肿瘤的恶性转化及其随后的生长、增殖和转移中起重要作用。临床前研究表明,PI3K/AKT/mTOR通路在膀胱癌中经常被激活。因此,这一通路被认为是膀胱癌治疗干预的候选通路,针对该通路不同成分的抑制剂正处于临床开发的不同阶段。在这里,重点介绍我们对PI3K/AKT/mTOR通路的最新研究进展,并讨论以该通路为靶点的治疗药物作为膀胱癌治疗药物的发展障碍及发展潜力。

Phosphatidylinositol 3-kinase(PI3K)/AKT/mammalian rapamycin target(mTOR)pathway plays an important role in malignant transformation and subsequent growth,proliferation and metastasis of human tumors.Pre-clinical studies have shown that PI3K/AKT/mTOR pathway is often activated in bladder cancer.Therefore,this path-way is considered as a candidate pathway for bladder cancer treatment intervention,and inhibitors targeting different components of this pathway are at different stages of clinical development.Here,we focus on the latest progress of our PI3K/AKT/mTOR pathway,and discuss the obstacles and potential of therapeutic drugs targeting this pathway as therapeutic drugs for bladder cancer.